Analysts peg Genentech bid at $107.50

How much might be enough for Genentech? Analysts expect Roche to hike its bid to $107.50 a share, on average, up from its first, rejected offer of $89 per share. At that price, the deal would be worth $53 billion. Report

Suggested Articles

FDA Building 2
Pharma

Alnylam scores FDA approval for rare liver disease med Givlaari

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

by Kyle Blankenship
congress
Pharma

FDA nominee Hahn promises to put science above politics

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

by Eric Sagonowsky
opdivo
Pharma

BMS' Opdivo-Yervoy duo fails to top Opdivo in adjuvant melanoma

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.

by Carly Helfand